Molecular diagnostics group Premaitha Health has signed an agreement with Coastal Genomics, a biotechnology engineering firm based in Vancouver, Canada, to develop advanced technologies for clinical DNA sequencing tests, it announced on Monday.
The AIM-traded firm said Coastal Genomics develops and markets automated solutions to address sample preparation needs across the medical diagnostics sector.

Under the agreement, Coastal Genomics would work with Premaitha to develop customised advanced technologies to enhance aspects of Premaitha Health's in vitro diagnostic product portfolio.

The technologies being developed would be "best in class", the Premaitha board said, and would work across different applications, including but not limited to reproductive health.

"In partnering with Coastal Genomics, we see a real opportunity to introduce improved processes which will optimise our existing workflow, reduce cost and improve overall efficiency of the screening process for our customers," said Premaitha Health chief executive officer Dr Stephen Little.

"Coastal Genomics have significant expertise in this field and we look forward to working together to develop this market leading technology."

Matthew Nesbitt, president at Coastal Genomics, added that his company was "thrilled" to be working closely with Premaitha.

"As a leading molecular diagnostics company, Premaitha has invaluable insight into the demands and requirements of our technology and we look forward to leveraging this expertise to deliver a customised solution for Premaitha that can be widely deployed for DNA sequencing."

Related share prices
Premaitha Health (NIPT) share price